Cargando…
A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
Neuropathological investigations report that in synucleinopathies with dementia, namely Parkinson’s disease (PD) with dementia (PDD) and dementia with Lewy bodies (DLB), the histopathological hallmarks of Alzheimer’s Disease (AD), in particular amyloid plaques, are frequently observed. In this study...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760640/ https://www.ncbi.nlm.nih.gov/pubmed/33256252 http://dx.doi.org/10.3390/diagnostics10121015 |
_version_ | 1783627380867203072 |
---|---|
author | Bellomo, Giovanni Paolini Paoletti, Federico Chipi, Elena Petricciuolo, Maya Simoni, Simone Tambasco, Nicola Parnetti, Lucilla |
author_facet | Bellomo, Giovanni Paolini Paoletti, Federico Chipi, Elena Petricciuolo, Maya Simoni, Simone Tambasco, Nicola Parnetti, Lucilla |
author_sort | Bellomo, Giovanni |
collection | PubMed |
description | Neuropathological investigations report that in synucleinopathies with dementia, namely Parkinson’s disease (PD) with dementia (PDD) and dementia with Lewy bodies (DLB), the histopathological hallmarks of Alzheimer’s Disease (AD), in particular amyloid plaques, are frequently observed. In this study, we investigated the cerebrospinal fluid (CSF) AD biomarkers in different clinical phenotypes of synucleinopathies. CSF Aβ42/Aβ40 ratio, phosphorylated tau and total tau were measured as markers of amyloidosis (A), tauopathy (T) and neurodegeneration (N) respectively, in 98 PD (48 with mild cognitive impairment, PD-MCI; 50 cognitively unimpaired, PD-nMCI), 14 PDD and 15 DLB patients, and 48 neurological controls (CTRL). In our study, CSF AD biomarkers did not significantly differ between CTRL, PD-MCI and PD-nMCI patients. In PD-nMCI and PD-MCI groups, A-/T-/N- profile was the most represented. Prevalence of A+ was similar in PD-nMCI and PD-MCI (10% and 13%, respectively), being higher in PDD (64%) and in DLB (73%). DLB showed the lowest values of Aβ42/Aβ40 ratio. Higher total tau at baseline predicted a worse neuropsychological outcome after one year in PD-MCI. A+/T+, i.e., AD-like CSF profile, was most frequent in the DLB group (40% vs. 29% in PDD). |
format | Online Article Text |
id | pubmed-7760640 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77606402020-12-26 A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies Bellomo, Giovanni Paolini Paoletti, Federico Chipi, Elena Petricciuolo, Maya Simoni, Simone Tambasco, Nicola Parnetti, Lucilla Diagnostics (Basel) Article Neuropathological investigations report that in synucleinopathies with dementia, namely Parkinson’s disease (PD) with dementia (PDD) and dementia with Lewy bodies (DLB), the histopathological hallmarks of Alzheimer’s Disease (AD), in particular amyloid plaques, are frequently observed. In this study, we investigated the cerebrospinal fluid (CSF) AD biomarkers in different clinical phenotypes of synucleinopathies. CSF Aβ42/Aβ40 ratio, phosphorylated tau and total tau were measured as markers of amyloidosis (A), tauopathy (T) and neurodegeneration (N) respectively, in 98 PD (48 with mild cognitive impairment, PD-MCI; 50 cognitively unimpaired, PD-nMCI), 14 PDD and 15 DLB patients, and 48 neurological controls (CTRL). In our study, CSF AD biomarkers did not significantly differ between CTRL, PD-MCI and PD-nMCI patients. In PD-nMCI and PD-MCI groups, A-/T-/N- profile was the most represented. Prevalence of A+ was similar in PD-nMCI and PD-MCI (10% and 13%, respectively), being higher in PDD (64%) and in DLB (73%). DLB showed the lowest values of Aβ42/Aβ40 ratio. Higher total tau at baseline predicted a worse neuropsychological outcome after one year in PD-MCI. A+/T+, i.e., AD-like CSF profile, was most frequent in the DLB group (40% vs. 29% in PDD). MDPI 2020-11-26 /pmc/articles/PMC7760640/ /pubmed/33256252 http://dx.doi.org/10.3390/diagnostics10121015 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bellomo, Giovanni Paolini Paoletti, Federico Chipi, Elena Petricciuolo, Maya Simoni, Simone Tambasco, Nicola Parnetti, Lucilla A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies |
title | A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies |
title_full | A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies |
title_fullStr | A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies |
title_full_unstemmed | A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies |
title_short | A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies |
title_sort | a/t/(n) profile in cerebrospinal fluid of parkinson’s disease with/without cognitive impairment and dementia with lewy bodies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760640/ https://www.ncbi.nlm.nih.gov/pubmed/33256252 http://dx.doi.org/10.3390/diagnostics10121015 |
work_keys_str_mv | AT bellomogiovanni atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies AT paolinipaolettifederico atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies AT chipielena atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies AT petricciuolomaya atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies AT simonisimone atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies AT tambasconicola atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies AT parnettilucilla atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies |